|Certain Patients with Type 2 Diabetes Less Likely to Suffer Heart Failure While Taking New Class of Antidiabetic Drug|
HealthCore study is the first to report a direct comparison of two new medication classes on risk of heart failure hospitalization
The study is the first to report a direct comparison of SGLT2 and DPP4
inhibitors on the risk of heart failure hospitalization. People with
type 2 diabetes are at increased risk of serious health complications,
and the risk of heart failure alone is four- to fivefold higher among
patients with diabetes than those without the condition. Patients with
diabetes also face a higher risk of recurrent heart failure, compared
with people without diabetes.
SGLT2 inhibitors and DPP4 inhibitors are the latest addition to the type 2 diabetes treatment arsenal and are recommended as second-line treatment after metformin. Both SGLT2 and DPP4 inhibitors have received attention for their effect on cardiovascular outcomes, with clinical trials finding a reduction in cardiovascular events, including heart failure admissions with empaglifozin and canagliflozin – both SGLT2 inhibitors -- compared to placebo. However, there has been very limited information on how these findings compare to patients who use other medications.
“This study provides further insight into the clinical benefits observed
in the real-world for individuals using certain classes of medications,
and the potential for reducing medical complications,” said
The HealthCore study found that the heart failure hospitalization risk is 32 percent lower for new users of SGLT2 compared to DPP4 medications. In most patients younger than 65 or without history of diabetic complications, there was no risk difference. The majority of the analyzed patients were younger than 65, or didn’t have complications, and there was no risk difference among those.
“Real world studies like this can support findings from clinical trials
and provide comparative effectiveness and safety of these medications
that have not been studied,” said
The study analyzed medical and pharmaceutical data from
About Anthem, Inc.
Anthem is working to transform health care with trusted and caring solutions. Our health plan companies deliver quality products and services that give their members access to the care they need. With over 74 million people served by its affiliated companies, including more than 40 million within its family of health plans, Anthem is one of the nation’s leading health benefits companies. For more information about Anthem’s family of companies, please visit www.antheminc.com/companies.
1 Edward W. PhD; Zhuo, Xiaohui PhD; Cheng, Yjling
J PhD; Albright, Ann L.PhD; Narayan, Venkat MD; Thompson, Theodore MS;
(2014). Trends in Lifetime Risk and Years of Life Lost Due to Diabetes